Abstract Purpose: The Global Initiative for Chronic Obstructive Lung Disease guidelines provide recommendations to manage chronic obstructive lung disease (COPD) exacerbations. This study assessed the management of inpatient COPD exacerbations at an urban teaching hospital. Methods: A retrospective cohort analysis of adults admitted between December 2010 and August 2012 with a COPD exacerbation was conducted. Patient demographics, length of stay (LOS), Charlson comorbidity score, inpatient pulmonary medications, and 30-day readmission were collected. Descriptive statistics characterized guideline adherence and readmission. Results: 94 patients were included with median LOS of 3 days (interquartile range [IQR]: 1-5 days) and median Charlson comorbidity score of 6 (IQR: 5-8). All patients received an inhaled short-acting beta agonist, and 52 (55.3%) also received an inhaled short-acting anticholinergic. Seventy-eight (83%) received systemic corticosteroids, of which 3 received guideline-recommended doses. Sixty-four (68.1%) received antibiotics for a pulmonary indication, of which 71.9% received appropriate antibiotics per indication. Of the 94 patients, 2 were managed in complete adherence with GOLD recommendations. A total of 24 (25.5%) patients were readmitted within 30 days of discharge, 9 of these for COPD. Conclusion: COPD exacerbation treatment deviated from GOLD recommendations. This provides opportunities for further optimization of treatment of COPD exacerbations.
Background
Chronic obstructive pulmonary disease (COPD) is the third leading cause of morbidity and mortality in the United States, accounting for 2.7 million deaths and health-care resource costs exceeding US$50 billion annually. [1] [2] [3] The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines provide evidence-based recommendations for the inpatient management of severe COPD exacerbations. 4 Although these practice guidelines are updated yearly, physicians face many challenges managing COPD, and disease control remains suboptimal. 5 Inpatient recommendations for the management of an acute exacerbation of COPD (AECOPD) include the use of short-acting bronchodilators, systemic corticosteroids, and antibiotics in patients with cardinal symptoms (ie, dyspnea, chronic cough, and sputum production) or those requiring mechanical ventilation. Other components of COPD management include the administration of influenza and pneumococcal vaccinations to reduce future exacerbations. Based on limited available literature, it is unclear whether clinicians consistently adhere to these guidelines in an urban teaching hospital. The purpose of this study was to assess the management of inpatient COPD exacerbations with the objective of assessing adherence to GOLD guidelines and evaluating readmission rates following inpatient COPD management.
Methods
We performed a retrospective cohort analysis of all patients discharged with an International Classification of Diseases, Ninth Revision (ICD-9) code indicating a diagnosis of COPD between December 2010 and August 2012. This study took place at a 506-bed, urban academic hospital in Detroit, Michigan, which utilizes computer prescriber order entry and bar code technology to document medication administration. The study was approved by the institutional review board. All data were de-identified and stored in a password-protected computer.
Inclusion and Exclusion Criteria
Patients were eligible for inclusion if they were between 18 and 89 years of age and were admitted to an inpatient unit with any of the following ICD-9 codes: 490 bronchitis, not specified as acute or chronic; 491 chronic bronchitis; 492 emphysema; 493.2 chronic obstructive asthma; or 496 chronic airway obstruction, not elsewhere classified. Included patients also had documented shortness of breath due to COPD exacerbation in an initial inpatient note.
Data Collection
The following data were collected for all patients based on electronic medical record review: basic demographic information (ie, sex, age, race, height, weight, and renal function), length of stay, comorbid conditions, prescribed pulmonary medications on admission and discharge, influenza and pneumococcal vaccine administration history, use of noninvasive and invasive mechanical ventilation, and 30-day readmission rates. The Charlson comorbidity score was calculated for each patient based on collected data. This score predicts mortality risk based on comorbid conditions, and scores range from 0 to greater than 5, with 0 being the lowest risk and 5 or more having the greatest risk of mortality. 6 Season of admission was also collected (winter: December through February, spring: March through May, summer: June through August, and fall: September through November).
Definition of Appropriate Therapy
Appropriateness of therapy was determined using the evidencebased GOLD guidelines. The guidelines were updated midway during the study period, which had an impact on the therapies defined as "appropriate." Therefore, pharmacotherapy recommendations provided in either the 2010 or 2011 GOLD guidelines were deemed appropriate for this study. 7, 8 Appropriate therapy was defined as follows: short-acting beta-agonist (SABA) with or without a short-acting antimuscarinic agent (SAMA) as a nebulized solution or metered dose inhaler (MDI), systemic (intravenous or oral) corticosteroid dosing 30 to 40 mg per day of prednisone, and an antibiotic for a pulmonary indication (bronchitis, COPD, community acquired pneumonia [CAP] , and health-care-associated pneumonia [HCAP]) based on respective guideline recommendations for empiric antibiotic therapy.
Other Inpatient COPD Measures
Documentation of vaccinations was also assessed for all patients and was classified based on whether they received a pneumococcal (23 valent) and annual influenza vaccine during either a past or a current admission. Finally, we evaluated the use of mechanical and nonmechanical ventilation for all patients included.
Statistical Analysis
A convenience sample of approximately 100 patients were randomly selected. Descriptive statistics were used to characterize guideline adherence and readmission rates. Continuous data were summarized using medians and interquartile ranges. Categorical variables were summarized as counts and percentages. Chi-square tests were used to test differences in categorical variables. All statistical testing was considered significant when 2-tailed P values were <.05. Analyses were generated using JMP1, version 11 (SAS Institute Inc, Cary, North Carolina).
Results
Of the 611 patients identified during the study period, 94 patients were included in the analysis ( Figure 1 ). Patient demographics for the study population are listed in Table 1 . The majority of our patients were African American, which is consistent with the population at this institution. The median Charlson Comorbidity score is 6, indicating a high risk of 1-year mortality.
Prescribing Patterns
All 94 (100%) patients included in the study received an SABA as a nebulized solution or MDI. Of those patients receiving an SABA, 52 (55.3%) also received a SAMA as a nebulized solution or MDI. There were 78 (83%) patients who received systemic (intravenous or oral) corticosteroids; 3 (3.8%) received a steroid equivalent dose between 30 and 40 mg of prednisone. Four (5.1%) of the 78 patients received doses equivalent to less than 30 mg of prednisone, and 71 (91%) of the 78 patients received doses equivalent to greater than 40 mg of prednisone. When assessing patients receiving antibiotics, 64 (68.1%) received antibiotics for a pulmonary indication (bronchitis, COPD, CAP, or HCAP). Of these 64 patients, 46 (71.9%) received appropriate antibiotics based on the indication. An additional 5 patients received antibiotics for nonpulmonary indications. However, dose and duration of antibiotics were not assessed. 
Adherence to GOLD Guidelines
A stepwise analysis of adherence to GOLD guidelines is listed in Figure 2 . Based on this stepwise analysis, all patients (100%) in the study received appropriate bronchodilator therapy (SABA with or without SAMA). Only 3 (3.9%) of the 94 patients received appropriate systemic corticosteroid dosing. Of these 3 patients, only 2 patients received appropriate empiric antibiotic therapy.
Other Measures
Documentation of vaccinations for all patients included in the study is listed in Figure 3 . Rate of documented influenza and pneumococcal vaccinations remained consistent throughout the winter and spring months (51%-56% for December through May) and decreased slightly in the fall (44%). During the summer months, influenza vaccination documentation decreased (10%), while pneumococcal vaccination documentation remained consistent (62%). In addition, 45 (89.4%) patients required noninvasive mechanical ventilation, 1 (1.1%) patient received invasive mechanical ventilation, and 9 (9.6%) patients did not receive any oxygen therapy.
Readmission Rates
A total of 24 (25.5%) patients were readmitted within 30 days of discharge, and 9 (9.6%) patients were readmitted for a COPD diagnosis. Of the 9 patients who were readmitted for a COPD diagnosis, 4 did not receive antibiotics or steroids during admission, and 1 patient received antibiotics but not steroids. By season, winter had the most 30-day readmissions with 2.3 readmissions per month, compared to readmissions in spring, summer, and fall (1.7, 2, and 2 readmissions per month, respectively). This was not consistent with the overall number of COPD admissions by season. Overall, a greater number of admissions per month occurred in the spring (11 admissions/ month) versus the summer, fall, or winter (7, 5.3, and 8 admissions, respectively).
Discussion
Our analysis suggests that the majority of patients admitted with AECOPD were not treated in accordance with evidencebased guidelines at our institution. Given that appropriate management of AECOPD is vital to minimize the impact of the current exacerbation and reduce the burden of the disease, it is important to standardize treatment. 4, 7, 8 Available literature, however, demonstrates a consistent variation in provider adherence to evidence-based guidelines for the treatment of AECOPD.
9-11 A retrospective analysis of 273 patients presenting to the emergency department (ED) in Australia with an AECOPD found that SABAs and systemic corticosteroids were administered in only 72.4% and 56.6% of patients, Figure 3 . Vaccination status documentation.
respectively. 10 Our study had a higher administration rate of SABAs and corticosteroids than that found in the Australian analysis. Although our rate of corticosteroid administration was higher, corticosteroid dosing greatly varied from guideline recommendations. Additionally, of the 71 patients who received daily doses of greater than 40 mg of prednisone, there was variability in the dosing schedule and the duration.
A subsequent quasi-experimental study of 420 patients hospitalized with a discharge diagnosis of COPD reported improved adherence to clinical guidelines and a reduction in the total dose of corticosteroids administered by 51% following the implementation of an electronic order set. 12 The high doses of corticosteroids prescribed in the analysis prior to intervention were similar to the findings of our study. Another prospective multicenter cohort study completed in Canada found low rates of steroid (62%) and antibiotic use (28%) for AECOPD in the ED compared to recommendations available in clinical practice guidelines from 1987 to 2001. 13 There is a paucity of data describing appropriate antibiotic use in the acute treatment of COPD exacerbations. Our analysis showed that nearly 75% of patients were treated with antibiotic therapy that was deemed appropriate based on whether the chosen antimicrobial therapy was in agreement with evidence-based recommendations for the indication documented within the electronic medical record. Culture results were not available for all patients in the current trial; therefore, evaluation of optimal antimicrobial therapy based on culture and sensitivity results was not possible.
The documentation of pneumococcal vaccination was consistent year-round. The documentation of influenza vaccination status was consistent throughout most of the year but was very low in the summer months (10%) The flu season in North America is in the late fall through early spring; therefore, it is not surprising that rates of documentation of influenza vaccination status observed in this study fell during the summer months. While vaccinations are not administered during the summer months, it is important to maintain consistent documentation practices. A recent retrospective analysis of 900 patients with COPD in Northern Spain reported that patients with more severe COPD (GOLD stages 3 and 4, 29.7% of patients) experienced a greater protective effect against severe COPD exacerbations requiring hospitalization in the year following influenza vaccination than patients with less severe COPD (GOLD stages 1 and 2, 70.3%).
14 The pneumococcal vaccination was not associated with a similar protective effect. In this analysis, patients with mild COPD were vaccinated at a rate of 65.3% versus 52% of patients with very severe COPD (P ¼ .67). This is a concerning trend, as other studies have also demonstrated protective effects of influenza vaccination, as well as pneumococcal vaccination, against future severe exacerbations, further supporting the importance of vaccinations in the setting of COPD. 14, 15 Therefore, it is important to ensure that previously unvaccinated patients are vaccinated in the acute setting. Documentation of vaccination is vital to ensuring patients are appropriately managed. Based on our findings in this analysis, documentation during hospital admission could be improved.
Our analysis found that initial admission rates for AECOPD were highest in the spring, which differs from other larger studies demonstrating that most exacerbations occur in the winter (December through February). 16 Subsequent readmission for AECOPD in our study more commonly occurred in the winter, which aligns with previously published findings. Furthermore, our analysis did not assess which factors may have been present to place a patient at higher risk for readmission. A recent analysis found that previous noninvasive ventilation due to AECOPD, COPD assessment test score, 6-minute walk distance, and number of admissions for AECOPD in the previous year were independently associated with time to first readmission. 17 It is unknown whether these factors were present in the patients in our analysis. One factor that may play a role in our winter readmission rate is the ambient temperatures in Detroit, Michigan. A population-based study conducted in a metropolitan area found that for each degree Celsius decrease in mean weekly temperature, hospital admissions increased by approximately 5%. 18 Another factor that may play a role in readmissions was the lack of steroid use in some patients. Although the sample size was too small to draw conclusions, approximately half of the patients readmitted did not receive steroids. Given that steroids are a mainstay of guideline-based therapy, this warrants further investigation. This study is not without limitations. Given the retrospective nature of the study design, there is risk for confounding factors. In addition, selection bias may be present as patients were only included in the study if they had both been assigned an ICD-9 code for COPD exacerbation and had shortness of breath recorded in the initial progress note for the admission. As with any retrospective evaluation, documentation in the electronic medical record is reliant on provider and patient recall and accurate information recording. While adequate selection of the antibiotic was evaluated, we did not focus on dosing and duration due to the lack of specific recommendations in GOLD guidelines. Likewise, duration of corticosteroid therapy was not evaluated, as it generally extended beyond inpatient management. Due to the short follow-up time of the study and small sample size, seasonal readmission data for AECOPD may not reflect actual trends. Another limitation to this study is the changes in some of the guideline recommendations during the study period. We attempted to control for this by evaluating the data with both sets of guidelines, specifically the antibiotic therapy recommendations. Despite these limitations, this study provides new data regarding adherence to guideline-based therapy in the hospital setting. This analysis also provides a foundation for quality improvement projects and additional studies surrounding ways to improve adherence to guidelines including clinical bundle services.
Conclusion
While all patients received some guideline-recommended therapy, the majority had aspects of their therapy that deviated from GOLD recommendations. This provides opportunities for further optimization of the treatment of COPD exacerbations.
